MAPK3 and Hodgkins lymphoma: Preliminary experiments involving a panel of HL cell lines (L-540, SUP-HD1, KM-H2, L-428, HDLM-2; Supplementary Fig. S1) and lymph node biopsies from HL patients (n = 10; Supplementary Fig. S2) demonstrated constitutively high phosphorylation levels of ERK1/2 and AKT with no differences between chemosensitive and chemoresistant patients, suggesting that combined ERK1/2 and AKT inhibition with AEZS-136 might have therapeutic relevance.